Antares Pharma, Inc. has announced the approval of Xyosted (testosterone enanthate) injection by the US Food and Drug Administration (FDA) for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Xyosted is the first FDA-approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector. Antares Pharma, Inc., is headquartered in Ewing, NJ.
Dosage/administration: Xyosted has been approved in 3 dosage strengths, 50 mg, 75 mg, and 100 mg.
Adverse reactions: The most commonly reported adverse reactions (>5%) were increased hematocrit, hypertension, increased PSA, injection site bruising, and headache.
Antares receives FDA approval of Xyosted (testosterone enanthate) injection for testosterone replacement therapy in adult males. [news release]. Ewing, NJ: Antares Pharma, Inc. October 1, 2018. https://www.antarespharma.com/application/files/2715/3835/7488/XYOSTED_FDA_Approval_Final.pdf. Accessed October 3, 2018.
This Week's Must Reads
Medical Costs Before and After Diabetes Diagnosis, Diabetes Care; ePub 2018 Nov 19; Shrestha, et al
BMI a Risk Factor for T2D Regardless of HDP History, Diabetes Care; ePub 2018 Nov 19; Timpka, et al
Heavy Drinkers at Risk for Suboptimal Weight Loss, Obesity; ePub 2018 Nov 13; Chao, Wadden, et al
Infertility in Women May Be Linked with CV Health , Fertil Steril; ePub 2018 Nov 17; Gleason, et al
Online Diabetes Prevention for Older Veterans, Diabetes Care; ePub 2018 Oct 30; Lee, et al
Must Reads in FDA Actions
FDA Approves Xyosted for Testosterone Replacement, Antares Pharma news release; 2018 Oct 1
FDA Approves Implantable Glucose Sensor Device, FDA Web site; 2018 Jun 21
FDA Approves Updates to Tresiba Label, Novo Nordisk news release; 2018 Mar 26
FDA Approves Integrated Continuous GM System, FDA Web site; 2018 Mar 27
FDA Approves New Guardian Sensor 3 Arm Indication , Medtronic news release; 2018 Feb 26